Interventions for enhancing adherence to treatment in adults with bronchiectasis by McCullough, Amanda et al.
Interventions for enhancing adherence to treatment in adults with
bronchiectasis
McCullough, A., Thomas, E. T., Ryan, C., Bradley, J., O'Neill, B., Elborn, J., & Hughes, C. (2015). Interventions
for enhancing adherence to treatment in adults with bronchiectasis. Cochrane database of systematic reviews
(Online), (11), 1-16. [CD011023]. DOI: 10.1002/14651858.CD011023.pub2
Published in:
Cochrane database of systematic reviews (Online)
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This work is made available online in accordance with
the publisher’s policies. Please refer to any applicable terms of use of the publisher.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:06. Aug. 2018
Cochrane Database of Systematic Reviews
Interventions for enhancing adherence to treatment in adults
with bronchiectasis (Review)
McCullough A, Thomas ET, Ryan C, Bradley JM, O’Neill B, Elborn S, Hughes C
McCullough A, Thomas ET, Ryan C, Bradley JM, O’Neill B, Elborn S, Hughes C.
Interventions for enhancing adherence to treatment in adults with bronchiectasis.
Cochrane Database of Systematic Reviews 2015, Issue 11. Art. No.: CD011023.
DOI: 10.1002/14651858.CD011023.pub2.
www.cochranelibrary.com
Interventions for enhancing adherence to treatment in adults with bronchiectasis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
8DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
16DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
16INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iInterventions for enhancing adherence to treatment in adults with bronchiectasis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Interventions for enhancing adherence to treatment in adults
with bronchiectasis
Amanda McCullough1, Elizabeth T Thomas1 , Cristin Ryan2, Judy M Bradley3,4, Brenda O’Neill5, Stuart Elborn4,6, Carmel Hughes
7
1Centre for Research in Evidence-Based Practice (CREBP), BondUniversity, Gold Coast, Australia. 2School of Pharmacy, Royal College
of Surgeons in Ireland, Dublin 2, Ireland. 3TheWellcome Trust-Wolfson Northern Ireland Clinical Research Facility U Floor, Queen’s
University Belfast, Belfast, UK. 4Department of Respiratory Medicine, Belfast Health and Social Care Trust, Belfast, UK. 5Centre for
Health and Rehabilitation Technologies (CHaRT), Institute of Nursing and Health Research, Ulster University, Newtownabbey, UK.
6Centre for Infection and Immunity, Queen’s University Belfast, Belfast, UK. 7School of Pharmacy, Queen’s University Belfast, Belfast,
UK
Contact address: Amanda McCullough, Centre for Research in Evidence-Based Practice (CREBP), Bond University, Gold Coast,
Queensland, Australia. amandamccullough104@gmail.com, amccullo@bond.edu.au.
Editorial group: Cochrane Airways Group.
Publication status and date: Edited (no change to conclusions), published in Issue 8, 2017.
Citation: McCullough A, Thomas ET, Ryan C, Bradley JM, O’Neill B, Elborn S, Hughes C. Interventions for enhancing adherence
to treatment in adults with bronchiectasis. Cochrane Database of Systematic Reviews 2015, Issue 11. Art. No.: CD011023. DOI:
10.1002/14651858.CD011023.pub2.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Bronchiectasis is characterised by a widening of the airways, leading to excess mucus production and recurrent infection. It is more
prevalent in women and those in middle age. Many patients with bronchiectasis do not adhere to treatments (medications, exercise
and airway clearance) prescribed for their condition. The best methods to change these adherence behaviours have not been identified.
Objectives
To assess the effects of interventions to enhance adherence to any aspect of treatment in adults with bronchiectasis in terms of adherence
and health outcomes, such as pulmonary exacerbations, health-related quality of life and healthcare costs.
Search methods
We searched the Cochrane Airways Group Specialised Register (CAGR), which contains trial reports identified through systematic
searches of CENTRAL, MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, from inception to October 2015.
Selection criteria
We planned to include randomised controlled trials (RCTs) of adults with bronchiectasis that compared any intervention aimed at
enhancing adherence versus no intervention, usual care or another adherence intervention. We excluded studies of those who had
bronchiectasis due to cystic fibrosis.
Data collection and analysis
Two review authors (AMcC and ET) independently screened titles, abstracts and full-texts of identified studies.
Main results
Searches retrieved 36 studies reported in 37 articles; no eligible studies were identified.
1Interventions for enhancing adherence to treatment in adults with bronchiectasis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Authors’ conclusions
We did not identify any studies that assessed the effect of interventions to enhance adherence to treatment in bronchiectasis. Adequately
powered, well-designed trials of adherence interventions for bronchiectasis are needed.
P L A I N L A N G U A G E S U M M A R Y
How can adults with bronchiectasis be encouraged to take treatments as prescribed by their health professional?
Review question
How can adults with bronchiectasis be encouraged to complete treatments such as medications, breathing exercises or other exercise as
prescribed by their health professional?
Background
Bronchiectasis is caused by a widening of the airways. People with bronchiectasis have too much mucus in their lungs and often
suffer from chest infections. Bronchiectasis occurs more commonly in women, and those in middle age. Treatments prescribed for
bronchiectasis include inhalers, nebulisers and airway clearance physiotherapy. Doing all of these correctly can take up a lot of time
every day. Many people with bronchiectasis find it difficult to fit these treatments into their daily lives.
Taking treatments in the way they have been prescribed by a health professional is called adherence. People with bronchiectasis who
have low adherence to treatments like nebulised antibiotics have more chest infections than those with high adherence. We wanted to
find out ways of encouraging adults with bronchiectasis to take treatments as prescribed by their health professional.
Search date
The evidence is current to October 2015.
Key results
We identified 37 reports but did not find any studies that tested ways to improve adherence to treatment. Properly-designed research
studies that include an appropriate number of people with bronchiectasis are needed to answer this question.
B A C K G R O U N D
Description of the condition
More than 600 million people worldwide suffer from chronic res-
piratory disease (WHO 2007), leading to 4.2 million deaths an-
nually (WHO 2010). Bronchiectasis is characterised by chronic
dilation of the airways, leading to excess sputum production and
recurrent infection (Pasteur 2010). It is an under-diagnosed and
under-investigated condition (Gibson 2013). Research into new
treatments is urgently required to improve the health status of pa-
tients with this condition (Gibson 2013). The global prevalence
of bronchiectasis is currently not known. The most recent preva-
lence study, conducted in the United States, demonstrated that
prevalence of the condition is increasing at a rate of 8.7% annu-
ally, with an 8-year prevalence of 1106 per 100,000 of the pop-
ulation (Seitz 2012). Bronchiectasis-associated annual healthcare
costs were estimated at US$630 million in 2005 (Weycker 2005),
and bronchiectasis-associated hospital admissions range between 2
and 6 per 100,000 in Europe (Gibson 2013). Given the recognised
under-diagnosis of this condition, it is likely that prevalence and
the associated healthcare burden are even greater than reported.
Description of the intervention
Patients with bronchiectasis are commonly prescribed a complex
regimen of medication, airway clearance techniques and exercise
(Pasteur 2010; Chang 2015). However, there is insufficient high-
quality evidence of their effectiveness (Franco 2003; Evans 2007;
Pizzutto 2010; Lee 2013; Goyal 2014; Hart 2014; Wilkinson
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2014) and no licensed therapies for the treatment of bronchiec-
tasis. New therapies are being adapted and tested in patients with
bronchiectasis (Altenburg 2013; Bilton 2013; Haworth 2013;
Serisier 2013; Wilson 2013), and it is likely that the treatment
burden for those with bronchiectasis will continue to grow as some
of these become licensed treatments. This burden may lead to fur-
ther reductions in adherence to treatment.
Adherence is defined as “the extent to which a person’s be-
haviour - taking medication, following a diet and/or executing
lifestyle changes - correspondswith agreed recommendations from
a healthcare provider” (WHO 2003). Recent data suggest that as
few as 53% of patients with bronchiectasis are adherent to medica-
tion and41%to airway clearance (McCullough 2014a). This is im-
portant because those who are non-adherent to inhaled antibiotics
have significantly more pulmonary exacerbations (McCullough
2014a) and a shorter time to first exacerbation (Haworth 2013).
Interventions to enhance adherence are needed but little is known
about the types of adherence interventions that have been used in
bronchiectasis or which, if any, are effective.
How the intervention might work
Adherence is a complex behavioural process. Adherence interven-
tions use educational, psychological and behavioural techniques,
in isolation or in combination with each other, to alter adherence
behaviour. However, education alone is insufficient to alter ad-
herence behaviour (Haynes 2008). Enhanced adherence may lead
to improved health outcomes, including reductions in pulmonary
exacerbations and in healthcare costs for people with bronchiec-
tasis. Patients may experience improved health-related quality of
life as a consequence of enhanced adherence.
Why it is important to do this review
Low adherence is associated with more frequent pulmonary exac-
erbations for patients with bronchiectasis (McCullough 2014a).
Therefore, enhancing adherence has the potential to lead to im-
proved health outcomes in this patient population. Little is known
about the types of adherence interventions that have been used
in bronchiectasis and which, if any, are effective. We planned to
analyse randomised controlled trials to determine the content of
the interventions that have been tested in this population and their
effectiveness in enhancing adherence and health outcomes.
O B J E C T I V E S
To assess the effects of interventions to enhance adherence to any
aspect of treatment in adults with bronchiectasis in terms of ad-
herence and health outcomes, such as pulmonary exacerbations,
health-related quality of life and healthcare costs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include randomised controlled trials (RCTs). We
planned to include studies reported as full text, those published as
abstract only and unpublished data. We also planned to include
both parallel and cross-over group designs.
Types of participants
Adults (18 years of age or older) with bronchiectasis diagnosed by
high-resolution computed tomography were eligible for inclusion.
Weplanned to include both thosewho are acutely unwell and those
who were stable. We excluded participants with bronchiectasis
caused by underlying cystic fibrosis. We also planned to include
studies that contained only a subset of relevant participants, where
data were reported separately.
Types of interventions
We planned to include trials comparing any intervention aimed
at enhancing adherence (including self management, education,
service developments, reminders and other psychological and be-
havioural techniques) versus no intervention, usual care or another
adherence intervention. We excluded studies that compared ad-
herence between two different treatments without any adherence
intervention (e.g. those comparing adherence to one type of medi-
cation, airway clearance technique, inhaler, mask or nebuliser ver-
sus another) and those that merely report adherence to treatment.
Types of outcome measures
Reporting in the trial one ormore of the outcomes listed belowwas
not an inclusion criterion for the review. We planned to include
studies on the basis of type of study, participants and interventions.
We planned to extract data collected at the end of the intervention
period (i.e. after the last intervention) and at the end of the study
follow-up (i.e. the end of the study), if different fromdata obtained
at the end of the intervention period. Where appropriate, we also
planned to extract data collected at interim time points (i.e. data
collected at time points other than end of the intervention and
end of the study).
Primary outcomes
1. Adherence to at least one aspect of treatment (medication,
airway clearance, medical devices or physical activity) as
measured by direct (e.g. electronic monitoring, directly observed
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therapy) or indirect methods (e.g. self report, prescription refill
data).
2. Rate of, duration of or time to first pulmonary exacerbation
of bronchiectasis, defined according to the investigators’
definition.
Secondary outcomes
1. Time to hospitalisation, number of hospital admissions or
hospital days for a pulmonary exacerbation of bronchiectasis.
2. Pulmonary function measures (forced expiratory volume in
one second (FEV1), forced vital capacity (FVC), FEV1/FVC,
forced expiratory flow (FEF)25−75, peak expiratory flow (PEF)).
3. Health-related quality of life measured using a generic or
disease-specific tool (e.g. St George’s Respiratory Questionnaire,
Quality of Life Questionnaire-Bronchiectasis).
4. Exercise capacity as measured by any exercise capacity tool
(e.g. six-minute walk test, incremental shuttle walk test).
5. Healthcare costs including costs of intervention, costs of
devices and overall expenditures.
6. Any adverse events associated with adherence or non-
adherence to treatment.
Adherence to treatment is a primary outcome of this review, as this
is the key outcome that adherence interventions aim to change.
Reducing the frequency, duration of or time to pulmonary exac-
erbations, minimising hospital admissions, improving health-re-
lated quality of life and maintaining pulmonary function are key
clinical outcomes of bronchiectasis treatments (Pasteur 2010) and
thus have been chosen as the clinical outcomes for this review. To
judge whether interventions can be implemented in clinical prac-
tice, it is necessary to know the cost-effectiveness of the interven-
tion. Finally, to ensure patient safety, it is important to be aware
of any adverse events associated with the intervention.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group Spe-
cialised Register (CAGR), which is maintained by the Trials
Search Co-ordinator for the Group. The Register contains trial
reports identified through systematic searches of bibliographic
databases including the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED
and PsycINFO, and by handsearching of respiratory journals
and meeting abstracts (see Appendix 1 for further details). We
searched all records in the CAGR using the search strategy pro-
vided in Appendix 2. We also conducted a search of ClinicalTri-
als.gov (www.ClinicalTrials.gov) and theWorld Health Organiza-
tion (WHO) trials portal (www.who.int/ictrp/en/). We searched
all databases from the time of their inception up to October 2015,
and we imposed no restriction on language of publication.
Searching other resources
We planned to check reference lists of all primary studies and re-
view articles for additional references. We planned to search rele-
vant manufacturers’ websites for trial information. We planned to
search for errata or retractions from included studies published in
full text on PubMed (www.ncbi.nlm.nih.gov/pubmed) and report
within the review the date this was done.
Data collection and analysis
Selection of studies
Two review authors (AMcC and ET) independently screened titles
and abstracts for inclusion of all studies identified as a result of
the search and coded them as ’retrieve’ (eligible or potentially eli-
gible/unclear) or ’do not retrieve’. We retrieved the full-text study
reports/publications, and two review authors (AMcC and ET) in-
dependently screened the full text and identified studies for in-
clusion, and identified and recorded reasons for exclusion of inel-
igible studies. We resolved disagreements through discussion, or,
if required, consulted a third review author (CH). We identified
and excluded duplicates and collated multiple reports of the same
study, so that each study rather than each report was the unit of in-
terest in the review. We recorded the selection process in sufficient
detail to complete a PRISMA flow diagram and a Characteristics
of excluded studies table.
Data extraction and management
We planned to document study characteristics and outcome data
using a data collection form that had been piloted on at least one
study in the review. Two review authors (AMcC and ET) planned
to extract the following study characteristics from included studies.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
setting, withdrawals and date of study.
2. Participants: number of participants, mean age, age range,
gender, ethnicity, educational level, severity of condition,
diagnostic criteria, baseline lung function, smoking history,
inclusion criteria and exclusion criteria.
3. Interventions: description of the intervention including
duration of run-in, intervention and follow-up; type of
intervention (including its components (e.g. self management,
education, service developments, reminders and other
psychological and behavioural components), how and where it
was delivered, by whom and its theoretical rationale) and type of
control group.
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4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial and notable conflicts of interest of
trial authors.
Two review authors (AMcC and ET) planned to independently
extract outcome data from included studies.We planned to note in
the Characteristics of included studies table if outcome data were
not reported in a usable way. We aimed to resolve disagreements
by consensus or by involving a third review author (CH). One
review author (AMcC) planned to transfer data into the Review
Manager (RevMan 2014) file.Wewouldhave double-checked that
data had been entered correctly by comparing the data presented
in the systematic review versus information provided in the study
reports. A second review author (ETorCH)would have then spot-
checked study characteristics against the trial report to confirm
accuracy.
Assessment of risk of bias in included studies
Two review authors (AMcC and ET) planned to independently
assess risk of bias for each study using the criteria outlined in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). We would have resolved disagreements by discussion or by
involving another review author (CH). We then planned to assess
the risk of bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We planned to grade each potential source of bias as high, low
or unclear and provide this grading in the ’Risk of bias’ table
using a quote from the study report together with a justification
for our judgement. We planned to summarise the ’Risk of bias’
judgements across different studies for each of the domains listed.
We would have considered blinding separately for different key
outcomes when necessary (e.g. for unblinded outcome assessment,
risk of bias for hospital admissions may be very different than for
patient-reported adherence). When information on risk of bias
related to unpublished data or correspondence with a trialist, we
would have noted this in the ’Risk of bias’ table. We planned to
take into account the risk of bias of the included studies when
considering treatment effects for each outcome.
Assesment of bias in conducting the systematic
review
We conducted the review according to the published protocol
(McCullough 2014b).
Measures of treatment effect
We planned to analyse dichotomous data as odds ratios and con-
tinuous data as mean differences or standardised mean differences.
We planned to enter presented data as a scale with a consistent
direction of effect. We would have undertaken meta-analyses only
when this was meaningful (i.e. when treatments, participants and
the underlying clinical question were similar enough for pooling
to make sense). We would have provided a narrative description of
skewed data reported as medians and interquartile ranges. When
multiple trial arms were reported in a single trial, we planned to
include only the relevant arms.When two comparisons (e.g. inter-
vention A versus control and intervention B versus control) were
combined in the same meta-analysis, we would have halved the
control group to avoid double-counting.
Unit of analysis issues
For dichotomous data, we planned to report the proportion of
participants contributing to each outcome in comparison with
the total number randomly assigned. For continuous data, the
mean difference based on change from baseline would have been
preferred over the mean difference based on absolute values. The
unit of analysis would be the person. For cluster-randomised trials,
to avoid a unit of analysis error, sensitivity analysis would have
occurred at the participant level and would have incorporated
adjustment using the intra-class correlation coefficient (ICC). For
cross-over studies, we planned to extract data from the first period
(before cross-over), to avoid any cross-over effects.
Dealing with missing data
We planned to contact investigators or study sponsors to verify
key study characteristics and to obtain missing numerical outcome
data when possible (e.g. when a study was identified as an abstract
only). If this was not possible and the missing data were thought
to introduce serious bias, we would have explored the impact of
including such studies in the overall assessment of results by per-
forming a sensitivity analysis.
Assessment of heterogeneity
We planned to use the I² statistic to measure heterogeneity among
the trials in each analysis. If we identified moderate (I² = 30% to
60%) or substantial heterogeneity (I² = 50% to 90%) (Higgins
2011), we planned to report this and explore possible causes by
prespecified subgroup analysis.
Assessment of reporting biases
If we were able to pool more than 10 trials, we planned to create
and examine a funnel plot to explore possible small-study biases.
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Data synthesis
If a meta-analysis was appropriate, we would have used a fixed-
effect model. If heterogeneity could not have been explained by
the prespecified subgroup and sensitivity analyses, we planned to
perform a sensitivity analysis using the random-effects model. If
a meta-analysis was not appropriate, we planned to conduct a
narrative synthesis of included studies.
’Summary of findings’ table
We planned to create a ’Summary of findings’ table using the pri-
mary and secondary outcomes stated previously. We planned to
use the fiveGRADE considerations (study limitations, consistency
of effect, imprecision, indirectness and publication bias) to assess
the quality of a body of evidence as it related to the studies that
contributed data to the meta-analyses for the prespecified out-
comes. We would have used methods and recommendations de-
scribed in Section 8.5 and Chapter 12 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011) and planned
to use GRADEproGDT software (GRADEproGDT).We would
have justified all decisions to downgrade or upgrade the quality
of studies by using footnotes, and made comments to aid readers’
understanding of the review when necessary.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
1. Type of intervention delivered.
2. Healthcare professional who delivered intervention
(physician versus non-physician led, e.g. nurses compared with
physiotherapists, pharmacists and other professionals).
3. Clinical setting (hospital care versus community services).
4. Duration of intervention (one-off intervention compared
with more than one intervention).
5. Disease status (acute versus stable participants).
We planned to use the following outcomes in subgroup analyses.
1. Adherence to at least one aspect of treatment (medication,
airway clearance, medical devices or physical activity) as
measured by direct (e.g. electronic monitoring, directly observed
therapy) or indirect methods (e.g. self report, prescription refill
data).
2. Rate of, duration of or time to first pulmonary exacerbation
of bronchiectasis, defined according to the investigators’
definition.
We planned to use the formal test for subgroup interactions in
Review Manager (RevMan 2014). When both acute and stable
participants were included in a study, we planned to explore them
by subgroup analysis only if the results were reported separately.
Sensitivity analysis
We planned to carry out the following sensitivity analyses.
1. Sensitivity analysis excluding studies with a high risk of bias
based on the ’Risk of bias’ assessment.
2. Studies with less than 80% follow-up.
R E S U L T S
Description of studies
Results of the search
The electronic searches retrieved 37 articles reporting 36 studies,
including 2 publications reporting the same study (Caine 2002;
Sharples 2002). After screening of titles and abstracts, one study
(two articles: Caine 2002; Sharples 2002) was retrieved for full-
text review. We wanted to review the full text for Yang 2012. We
contacted the author to seek a full text but did not receive a re-
sponse. None of these studies met the inclusion criteria (Charac-
teristics of included studies; Figure 1).
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Figure 1. Study flow diagram.
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Included studies
No eligible studies were identified.
Excluded studies
We excluded one study that measured adherence (Caine 2002;
Characteristics of excluded studies).
Caine 2002 tested nurse- versus doctor-led care with the aim of
establishing equivalence in clinical outcomes including lung func-
tion and quality of life. The authors measured adherence to an-
tibiotics as a secondary outcome and found that in a subgroup of
participants using antibiotics, 100% (95% CI 89% to 100%) in
the nurse-led intervention and 81% (95% CI 63% to 93%) in
the doctor-led intervention reported being adherent to antibiotics
(n = 31, P = 0.02). The authors did not report if there were any
between-group differences in adherence to physiotherapy and in-
halers. This study was excluded because it compared two different
forms of treatment, nurse-led versus doctor-led care (much like
an equivalence study for a new medication) and did not aim to
enhance adherence.
Studies awaiting classification
We could not determine whether to include a further study (Yang
2012). We attempted to get access to a full text by contacting the
authors but we did not receive a reply. Based on information in
the abstract, they used amicro-blogging tool to encourage patients
with bronchiectasis to keep a daily record of their disease symp-
toms, treatments and perceived treatment effects. Its primary aim
appeared to be improved self-care. They also measured adherence
to treatment but did not report it in the abstract. This study could
not be included at this time because there was insufficient infor-
mation in the abstract to determine if the intervention aimed to
enhance adherence.
Risk of bias in included studies
No eligible studies were identified.
Effects of interventions
There are no data available as no eligible studies were identified.
D I S C U S S I O N
Summary of main results
This review did not find any randomised controlled trials of inter-
ventions to enhance adherence in bronchiectasis. This finding is
explained by a general lack of research into adherence in bronchiec-
tasis. To date, research efforts have tended to focus on identifying
new and effective treatments (De Soyza 2013), meaning that the
effect of adherence to these treatments has only recently been de-
scribed (Haworth 2013; McCullough 2014a). The effect of new
treatments for bronchiectasis will be limited if adherence contin-
ues to be as low as recently reported (McCullough 2014a). As new
treatments continue to develop, the ability to enhance adherence
may become even more important.
Overall completeness and applicability of
evidence
We did not include any studies in this review. We excluded one
study (reported in two articles) that measured adherence. Caine
2002 did not test an intervention designed to enhance adherence.
A further study (Yang 2012) is awaiting classification. The abstract
did not report sufficient information about the intervention tested
and the full publication could not be obtained from the authors.
Quality of the evidence
We did not include any studies in this review and could not assess
their quality.
Potential biases in the review process
We completed a comprehensive search, without restrictions on
language. However, we limited included studies to randomised
control trials involving adults There may have been a greater range
of interventions to examine if the review also incorporated other
study designs or included children with bronchiectasis. We in-
cluded any interventions aimed at enhancing adherence; how-
ever, this description is open to interpretation. Nieuwlaat 2014
included Caine 2002 in a Cochrane review of adherence interven-
tions, whereas we have excluded it from this review.
Agreements and disagreements with other
studies or reviews
We excluded a study by Caine 2002 as it did not aim to enhance
adherence, in the same way that a study determining equivalence
between one drug and another would not aim to enhance adher-
ence. However, it was included in a recent systematic review of
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adherence interventions for any disease (Nieuwlaat 2014). This
could be due to a very slight difference in the inclusion criteria,
in which the authors of Nieuwlaat 2014 stated that they would
include “interventions of any sort intended to affect adherence”
(Nieuwlaat 2014). The study comparing nurse- verus doctor-led
care will likely be included in a forthcoming update of a Cochrane
review (French 2003). We also excluded studies comparing one
treatment to another.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There are no studies determining the effects of interventions to
enhance adherence to treatment in bronchiectasis. The lack of
focus on interventions to enhance adherence reflects the general
lack of emphasis that has been placed on this orphan disease:
there is a lack of dedicated clinical funding (McCullough 2015;
Welsh 2015) and specialist staff for bronchiectasis (McCullough
2015); managing adherence is not a priority for some clinicians
(McCullough 2015); and others lack the skills and confidence to
challenge patients about adherence (McCullough 2015).Without
evidence-based interventions, clinicians do not know the most
effective ways to change patient adherence behaviour. Research to
determine effective interventions to enhance adherence is needed,
so that clinicians can use these interventions to provide optimal
care for their patients.
Implications for research
This comprehensive systematic review did not identify any inter-
ventions to enhance adherence in adults with bronchiectasis. An
intervention to Change Adherence to treatment iN BronchiEta-
sis (CAN-BE) is currently being developed (McCullough 2015).
This intervention has been theoretically derived and contains 12
behaviour change techniques, fromwhich an individually-tailored
intervention can be used with patients. This intervention is still
in development, prior to feasibility and pilot testing. It is clear
that a high-quality randomised controlled trial of an adherence
intervention for adults with bronchiectasis is needed to determine
its effects on adherence to treatment and clinical outcomes (pul-
monary exacerbations, health-related quality of life and hospital
admissions). Several challenges to this exist: separating interven-
tion effects from a potential Hawthorne effect of being monitored
as part of the study; developing an appropriate placebo interven-
tion to attempt to blind participants and health professionals; and
gaining adequate statistical power if cluster randomisation, or fac-
torial designs are required.
It is likely that these trials will need to be conducted across several
clinical centres to allow adequate patient recruitment. Infrastruc-
ture to support these types of studies is growing with the devel-
opment of the Bronchiectasis Research and Academic Network in
the United Kingdom (De Soyza 2013), the European Bronchiec-
tasis Registry (EMBARC 2015) and the Bronchiectasis Research
Registry in the United States (COPD Foundation 2015). How-
ever, the key challenge for research into this condition continues
to be the lack of a dedicated research funding stream.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Caine 2002 Intervention did not aim to enhance adherence to treatment
Characteristics of studies awaiting assessment [ordered by study ID]
Richmond 2016
Methods
Participants
Interventions
Outcomes
Notes
Yang 2012
Methods Randomized controlled trial
Participants 50 patients with bronchiectasis who visited a University Hospital
Interventions Intervention: Patients were trained to complete an online symptom diary using Sina Weibo
Control: Typical care with outpatient services
Outcomes Compliance with treatment
Notes
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (T he Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
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(Continued)
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Bronchiectasis search
1. exp Bronchiectasis/
2. bronchiect$.mp.
3. bronchoect$.mp.
4. kartagener$.mp.
5. (ciliary adj3 dyskinesia).mp.
6. (bronchial$ adj3 dilat$).mp.
7. or/1-6
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 BRONCH:MISC1
#2 MeSH DESCRIPTOR Bronchiectasis Explode All
#3 bronchiect*
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Medication Adherence
#6 MeSH DESCRIPTOR Patient Acceptance of Health Care Explode All
#7 MeSH DESCRIPTOR Patient Dropouts
#8 complian* or noncomplian* or non-complian*
#9 adhere* or nonadhere* or non-adhere*
#10 persist*
#11 refusal or refuse*
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#12 concord*
#13 co-operate*
#14 conform*
#15 accept*
#16 comply*
#17 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #4 and #17
[In search line #1, MISC1 denotes the field in which the reference record has been coded for condition, in this case, bronchiectasis]
WH A T ’ S N E W
Last assessed as up-to-date: 14 October 2015.
Date Event Description
7 July 2017 Amended New literature search run to assess the need to update this review. One potentially eligible ongoing study
identified and added to Studies awaiting classification.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We added the following to methods for future updates of this review: for cross-over studies, we planned to extract data from the first
period (prior to cross-over), to avoid any cross-over effects.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Bronchiectasis [∗therapy]; Patient Compliance [∗psychology]
MeSH check words
Adult; Humans
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